Joanna Chua (Ng)

Swan Genomics is an early stage, multi-disciplinary startup focused on commercialising an innovative new approach to DNA sequencing to deliver more accessible genomics data to existing and new markets.

We are a community-powered, industry agnostic VC fund investing in Australian and New Zealand based startups that have $100m+ revenue ambition. We invest at the earliest stages, once you’re ready to turn “after work” into “work”. Our investment process is imbued with a deep respect for founders’ time, intel, and courage. Founders are frequently subject to hellish, drawn-out due diligence processes, only to be unceremoniously knocked back despite their best efforts. We made a commitment to turn up for founders, and have designed a highly transparent process which adds value at every step. Our community is rallied around a shared goal: to invest in the next generation of Australia and New Zealand startups at the very earliest stage, and then support them on their long and arduous journey from improbability to outlier success. Our hivemind is our bedrock and our edge.

Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology. Our mission is to connect ground-breaking companies with the capital, expertise and networks they need to realise their potential on a global scale. Founded in 2014 and with offices in Sydney and Singapore, our unique approach to early-stage tech investment globally sees our VC Funds co-investing alongside members of Club Investible, our active, global investor syndicate and community.

Murdoch Childrens Research Institute (MCRI) is Australias largest child health research institute and is ranked among the top three globally for research quality and impact. Our team of 1,800+ researchers works across over 150 common and rare diseases and conditions affecting children and adolescents. From allergies and asthma, diabetes and mental health issues to cancer and rare genetic disorders, we are relentless in our pursuit to transform child health through research and give all children the opportunity to live a healthy and fulfilled life. Our story began in 1986, when world-leading philanthropist Dame Elisabeth Murdoch and genetics pioneer Professor David Danks imagined a better future for our children and established the original Murdoch Institute for Research in Birth Defects. Since then, MCRI has grown from a genetics research institute to a global leader in child health. Our work also goes beyond research. MCRI is one of the only research institutes in Australia to offer genetic testing via our subsidiary, the Victorian Clinic of Genetic Services (VCGS), to find answers for families of children with previously undiagnosed conditions. Operating in a unique model with The Royal Childrens Hospital and the University of Melbourne, MCRI is part of a great circle of healthcare and discovery – helping transform child health from the laboratories to clinics and out into communities.

Swan Genomics is an early stage, multi-disciplinary startup focused on commercialising an innovative new approach to DNA sequencing to deliver more accessible genomics data to existing and new markets.

We are a community-powered, industry agnostic VC fund investing in Australian and New Zealand based startups that have $100m+ revenue ambition. We invest at the earliest stages, once you’re ready to turn “after work” into “work”. Our investment process is imbued with a deep respect for founders’ time, intel, and courage. Founders are frequently subject to hellish, drawn-out due diligence processes, only to be unceremoniously knocked back despite their best efforts. We made a commitment to turn up for founders, and have designed a highly transparent process which adds value at every step. Our community is rallied around a shared goal: to invest in the next generation of Australia and New Zealand startups at the very earliest stage, and then support them on their long and arduous journey from improbability to outlier success. Our hivemind is our bedrock and our edge.

Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology. Our mission is to connect ground-breaking companies with the capital, expertise and networks they need to realise their potential on a global scale. Founded in 2014 and with offices in Sydney and Singapore, our unique approach to early-stage tech investment globally sees our VC Funds co-investing alongside members of Club Investible, our active, global investor syndicate and community.

Techbench Capital supports and represent startups and advises corporates on Corporate Venture Capital (CVC) strategy and implementation. Our goal is to accelerate impactful solutions by harnessing technologies such as Artificial Intelligence (AI) in variety of areas including healthcare, agriculture, smart cities, energy and other.